Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
NCT ID NCT07682649
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This phase 1 trial tests whether giving a higher first dose of the radioactive drug Lu-177-PSMA-617 can improve treatment for men with metastatic castration-resistant prostate cancer. The drug targets a protein on prostate cancer cells and delivers radiation to kill them. Researchers want to see if a stronger initial dose is safe and may work better than the standard six-dose schedule. The study enrolls about 20 men whose cancer has spread and no longer responds to hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lu-177-PSMA-617 (radioactive drug)
- What this could lead to
- If successful, this approach could make radioligand therapy more effective for advanced prostate cancer by giving a higher dose early, potentially improving tumor control.
- What could go wrong
- This is a small, early-phase safety study (20 participants). The higher first dose may cause more side effects, and it is unknown if it will improve outcomes compared to the standard schedule.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
- Supercharged immune cells take on Hard-to-Treat prostate cancer